StemExpress, LLC

StemExpress, LLC is a biotechnology company specializing in providing cellular products and services essential for advancing cell and gene therapy research. StemExpress, LLC was founded in 2010 in Folsom, US. The company focuses on supplying a range of cellular products including Leukopaks and other blood products to research institutions and biotechnology firms. Cate Dyer serves as the CEO and has an extensive background in the biotech industry.

The company has engaged in one funding deal, raising an undisclosed amount of seed funding from IndieBio and SOSV on June 22, 2018. StemExpress offers a comprehensive range of cellular products and services that play a crucial role in advancing cell and gene therapy research. Their core offerings include healthy and disease state Leukopaks, mobilized Leukopaks, and various blood and cellular products such as bone marrow, cord blood, and isolated cells. These products are primarily utilized by research institutions, biotechnology firms, and pharmaceutical companies involved in clinical trials and therapeutic development, adhering to Good Manufacturing Practice (GMP) regulations.

StemExpress caters to clients across North America, Europe, and Asia, enhancing patient access to innovative therapies globally. StemExpress operates under a B2B model, partnering with research organizations and biotechnology firms for transactions involving clinical-grade cellular products. Clients request specific volumes and types according to their research needs, with pricing structures tailored accordingly. Key products include GMP Leukopaks and mobilized Leukopaks, often supported by long-term service contracts that ensure continuity in supply as clinical trials progress.

As of June 22, 2018, StemExpress intends to leverage the recent seed funding from IndieBio and SOSV to support the development of new cellular products and expand into new markets. The company aims to enhance its product lineup and increase its geographical reach, particularly targeting the North American and European markets within the next few years.